Search hospitals > Florida > Fort Myers
Golisano Children's Hospital of Southwest Florida
Claim this profileFort Myers, Florida 33908
Global Leader in Leukemia
Global Leader in Tumors
Conducts research for Lymphoblastic Leukemia-Lymphoma
Conducts research for Lymphoma
Conducts research for Lymphoid Leukemia
166 reported clinical trials
2 medical researchers
Summary
Golisano Children's Hospital of Southwest Florida is a medical facility located in Fort Myers, Florida. This center is recognized for care of Leukemia, Tumors, Lymphoblastic Leukemia-Lymphoma, Lymphoma, Lymphoid Leukemia and other specialties. Golisano Children's Hospital of Southwest Florida is involved with conducting 166 clinical trials across 309 conditions. There are 2 research doctors associated with this hospital, such as Emad K. Salman and Jeffrey S. Dome.Area of expertise
1Leukemia
Global LeaderStage II
NTRK1 positive
NTRK positive
2Tumors
Global LeaderStage IV
Stage I
Stage II
Top PIs
Emad K. SalmanGolisano Children's Hospital of Southwest Florida7 years of reported clinical research
Expert in Tumors
Expert in Leukemia
65 reported clinical trials
125 drugs studied
Jeffrey S. DomeChildren's National Medical Center7 years of reported clinical research
Expert in Tumors
Expert in Brain Tumor
64 reported clinical trials
112 drugs studied
Clinical Trials running at Golisano Children's Hospital of Southwest Florida
Acute Myeloid Leukemia
Germ Cell Tumors
Acute Lymphoblastic Leukemia
Osteosarcoma
Acute Leukemia
Brain Tumor
Non-Hodgkin's Lymphoma
Langerhans Cell Histiocytosis
Tumors
Lymphoma
Venetoclax + Chemotherapy
for Acute Myeloid Leukemia
This trial is testing whether adding venetoclax to standard chemotherapy can help young patients with relapsed AML. Venetoclax works by blocking a protein that helps cancer cells survive, making it easier for the chemotherapy to kill them. The study aims to find better treatment options for these patients who have limited choices. Venetoclax has been shown to improve overall survival in older and unfit patients with newly diagnosed acute myeloid leukemia when combined with lower intensity therapies.
Recruiting2 awards Phase 34 criteria
Revumenib + Chemotherapy
for Relapsed/Refractory Leukemia
This phase II trial tests the safety and best dose of revumenib in combination with chemotherapy, and evaluates whether this treatment improves the outcome in infants and young children who have leukemia that has come back (relapsed) or does not respond to treatment (refractory) and is associated with a KMT2A (MLL) gene rearrangement (KMT2A-R). Leukemia is a cancer of the white blood cells, where too many underdeveloped (abnormal) white blood cells, called "blasts", are found in the bone marrow, which is the soft, spongy center of the bones that produces the three major blood cells: white blood cells to fight infection; red blood cells that carry oxygen; and platelets that help blood clot and stop bleeding. The blasts crowd out the normal blood cells in the bone marrow and spread to the blood. They can also spread to the brain, spinal cord, and/or other organs of the body. The leukemia cells of some children have a genetic change in which a gene (KMT2A) is broken and combined with other genes that typically do not interact with one another; this is called "rearranged". This genetic rearrangement alters how other genes are turned on or off in the cell, turning on genes that drive the development of leukemia. Patients with KMT2A rearrangement have higher risk for cancer coming back after treatment. Revumenib is an oral medicine that directly targets the changes that occur in a cell with a KMT2A rearrangement and has been shown to specifically kill these leukemia cells in preclinical laboratory settings and in animals. Drugs used in chemotherapy, such as vincristine, prednisone, asparaginase, fludarabine and cytarabine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial is being done to find out if the combination of revumenib and chemotherapy would be safe and/or effective in treating infants and young children with relapsed or refractory KMT2A-R leukemia.
Recruiting1 award Phase 2
Diagnostic Testing
for Pediatric Leukemia
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.
Recruiting1 award Phase 1 & 211 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Golisano Children's Hospital of Southwest Florida?
Golisano Children's Hospital of Southwest Florida is a medical facility located in Fort Myers, Florida. This center is recognized for care of Leukemia, Tumors, Lymphoblastic Leukemia-Lymphoma, Lymphoma, Lymphoid Leukemia and other specialties. Golisano Children's Hospital of Southwest Florida is involved with conducting 166 clinical trials across 309 conditions. There are 2 research doctors associated with this hospital, such as Emad K. Salman and Jeffrey S. Dome.